Liquidia settles all litigation with United Therapeutics
Liquidia (LQDA) settled all litigation with United Therapeutics (UTHR), agreeing to pay $380.7M in installments. The settlement resolves patent, trade secret, and antitrust disputes. Liquidia reported Q3 2026 YUTREPIA sales of $222.7M and expects to fund payments from sales and cash.
How this was made
The 30-second read
Why it matters
The cash flow implications are material for both firms, likely moving their shares in opposite directions.
Market read
First‑report settlement news with $380M cash flow impact; relevant for traders in biotech equities.
What to watch
Potential tax benefits from the settlement and any future licensing revenue for United Therapeutics.
Background
Liquidia and United Therapeutics were engaged in six lawsuits over a pulmonary‑hypertension patent. The settlement resolves all claims.
Ticker impact
Liquidia announced a $380.7M settlement payment to United Therapeutics, with $175M due within 30 days and further installments in 2027.
likely downward pressure as the market prices in the settlement cash drain
The settlement amount is material relative to Liquidia's cash ($396.1M) and will be funded from ongoing sales.
United Therapeutics will receive $380.7M from Liquidia under the settlement, with the first $175M payment due soon.
likely upward pressure as investors price in the sizable cash receipt
The settlement provides a significant cash boost without diluting equity.
Market effects
The settlement may affect the biotech/pulmonary‑hypertension niche by clarifying patent rights.
Both companies are US‑listed; impact is limited to US biotech equities.
Limited to investors tracking biotech litigation outcomes.
Counterpoint
The settlement could be seen as a win for Liquidia if it clears the patent dispute and allows focus on product sales.
Key entities
- companyLiquidia Corporation
Biotech firm paying the settlement.
- companyUnited Therapeutics Corporation
Recipient of the settlement cash.
